Published on: 2026-08-05
Updated on: 2026-08-05
The retail portion was not fully subscribed, the grey market implied an almost flat debut, and FY26 profit fell 15.3%. On 5 August 2026, Manipal Health still opened as much as 11.02% above its ₹590 issue price. An 8.25x institutional order book and ₹5,552.8 crore of planned debt repayment outweighed the weak retail and earnings signals.
Late institutional orders drove the surprise debut, with total subscription jumping from below 0.5x after the second day to 4.92x at the close.
Strong revenue growth failed to reach the bottom line as acquisition-led expansion more than doubled total borrowings.
Debt repayment will absorb 69.4% of the fresh issue, making lower finance costs the clearest route to stronger profit.
The opening valuation reached about 85x FY26 earnings, leaving rapid deleveraging and higher hospital utilisation as the two tests that must justify the premium.
Manipal Health’s final grey-market premium of ₹3 implied a listing near ₹593, barely above the ₹590 issue price. The completed order book changed sharply on the final bidding day, when overall subscription rose from below 0.5x after day two to 4.92x at the close.
Qualified institutional buyers drove the late acceleration. Non-institutional demand reached 1.02x, while retail subscription stopped at 0.93x. The demand profile was narrow but deep, with large institutions carrying far more weight than the muted retail and grey-market signals suggested.
Debt-heavy expansion absorbed much of Manipal Health’s operating growth. FY26 revenue reached ₹10,335.8 crore, while profit fell to ₹916.5 crore from ₹1,081.7 crore a year earlier.
Total borrowings more than doubled to ₹10,553.4 crore. Net debt, including lease liabilities, rose from 2.0x to 3.7x adjusted EBITDA.
Operating cash flow remained positive at ₹2,078.4 crore. The figures point to financing pressure rather than weak cash generation. Revenue and hospital activity continued to expand, but a larger share of that operating progress failed to reach net profit.
The ₹9,275.2 crore IPO included an ₹8,000 crore fresh issue and an offer for sale of about ₹1,275.2 crore. Manipal Health receives the fresh capital, while the offer-for-sale proceeds go to the selling shareholders.
The company will use ₹5,552.8 crore, or 69.4% of the fresh issue, to repay or prepay borrowings. Lower interest costs now provide the shortest route back to profit growth. Slow deleveraging would weaken the main financial argument behind the listing premium.
Including Sahyadri across the full year increases Manipal Health’s pro forma revenue and operating capacity, but lowers profit, margin and average revenue per occupied bed.
| Metric | Reported | Pro forma |
|---|---|---|
| Revenue | ₹10,335.8 cr | ₹10,935.6 cr |
| Profit | ₹916.5 cr | ₹684.9 cr |
| PAT margin | 8.87% | 6.26% |
| Operating beds | 6,227 | 6,878 |
| ARPOB | ₹68,938 | ₹66,14 |
The enlarged network adds 10.5% more operating beds, yet pro forma profit and margin move lower. Additional capacity has not produced equivalent earnings quality.
The pro forma gap also includes financing and accounting effects, so it cannot be read as a pure measure of Sahyadri’s hospital operations. It does show that acquisition-led scale requires further integration before its earnings contribution matches its added revenue and capacity.
Across the wider Manipal network, occupancy fell from 67.09% to 64.47% as capacity expanded, even as average revenue per occupied bed rose 8.9% to ₹68,938. ARPOB increased while occupancy declined, showing stronger revenue from used capacity and weaker utilisation across the enlarged network.
The ₹590 offer price valued Manipal Health at 76.9x FY26 diluted earnings, above the disclosed peer average of 70.3x. The ₹652 to ₹655 listing range raised the same trailing calculation to about 85x, roughly 21% above that benchmark.
Such a premium leaves little room for a slow debt reset or weak occupancy recovery. Lower finance costs must translate into stronger profit, while acquired hospitals need to improve utilisation without diluting margins.
The valuation does not require another year of 25% revenue growth. It requires a greater share of existing operating growth to reach the bottom line. The first post-listing results will show whether earnings are beginning to support the premium or whether expectations remain ahead of delivery.
Manipal Health listed on 5 August 2026 at ₹652 on the NSE and ₹655 on the BSE against an issue price of ₹590. The opening gains were 10.51% and 11.02%. A minimum lot of 25 shares was worth ₹1,550 to ₹1,625 more at the listing prices.
The ₹3 GMP failed to capture late institutional demand. Qualified institutional buyers subscribed 8.25x their allocation as the overall book strengthened sharply before bidding closed.
Occupancy declined from 67.09% to 64.47% as operating beds increased from 5,179 to 6,227. ARPOB still rose 8.9% to ₹68,938 and inpatient volumes grew 19.9%, showing stronger revenue and patient activity but slower utilisation of the enlarged capacity.
The listing range implied a trailing P/E near 85x, compared with the disclosed peer average of about 70.3x. The valuation is demanding on FY26 earnings and depends on debt repayment reducing finance costs and acquired capacity producing stronger profit.
Net leverage remained near 3.7x adjusted EBITDA and occupancy stood at 64.47% in FY26. Slow debt reduction, weak utilisation or another year in which revenue rises faster than profit would place greater pressure on the valuation.
Manipal Health’s first post-listing quarterly results will test whether IPO-funded debt repayment is reducing finance costs and strengthening earnings. Revenue growth alone will no longer be enough.
The listing priced in debt relief. The next results must show it in profit.
